As of August 2026 — with bellwether-specific fact discovery officially closed on June 10, 2026 — the hair relaxer lawsuit 2026 litigation has entered what many legal observers are calling its highest-stakes phase since consolidation. The litigation has grown to 11,877 pending cases as of July 1, 2026 — now the fourth-largest MDL in the country — while Judge Mary Rowland has taken direct control of the trial-selection process, scrapping the alternating-picks system and selecting the bellwether pool herself, with case-specific Daubert and summary judgment motions now due November 16, 2026 and first trials broadly expected in 2027. Here is everything you need to know about where the litigation stands right now.
MDL 3060 by the Numbers: Scale, Scope, and Why It Matters
MDL 3060 — formally styled In re Hair Relaxer Marketing Sales Practices and Products Liability Litigation — is consolidated in the Northern District of Illinois before Judge Mary M. Rowland. There were 11,877 plaintiffs in the federal hair relaxer MDL as of July 2026, in addition to cases pending in state courts. Total filings, including resolved matters, stand at 16,199. According to court records and MDL trackers, roughly 11,877 cases were pending as of July 1, 2026, making it now the fourth-largest active MDL in the nation. That volume represents a staggering concentration of cases alleging that chemical hair relaxers caused uterine cancer, endometrial cancer, and ovarian cancer in women who used them regularly over years or decades.
The litigation traces directly to a landmark 2022 study by the NIH National Institute of Environmental Health Sciences (NIEHS), which analyzed data from the Sister Study. The October 2022 NIH Sister Study followed nearly 34,000 women for about 11 years. Researchers found that women who used hair straightening products more than 4 times per year were 2.55 times more likely to develop uterine cancer. For frequent users, the lifetime risk increased from 1.64% to 4.05% by age 70. Approximately 60% of the study participants who reported using relaxers were Black women, a demographic disproportionately affected by both the products and the cancers at issue.
| MDL 3060 Key Metric | Figure | Source / Date |
|---|---|---|
| Active lawsuits (MDL docket) | 11,877 | Lawsuit Information Center, July 2026 |
| Total filings including resolved | 16,199 | MDL Update, August 2026 |
| Federal MDL size rank (active) | 4th largest | LlamaLab / Trial Lawyers United, July 2026 |
| NIH uterine cancer risk increase (frequent users) | 2.55x (lifetime risk: 1.64% → 4.05%) | MDL Update / NIH Sister Study, 2022 |
| Black women in NIH relaxer-user cohort | ~60% | LlamaLab, July 2026 |
| Bellwether cases (judge-selected, initial) | 3 (from 32-case pool) | MDL Update, August 2026 |
| Bellwether fact discovery close date | June 10, 2026 | MDL Update / Verus LLC |
| Summary judgment / Daubert deadline | November 16, 2026 | MDL Update / Verus LLC |
| Daubert general causation ruling (expected) | Q1 2027 | LeadGen Economy, June 2026 |
| First federal bellwether trials (projected) | Mid-2027 | MDL Update / LlamaLab, July–August 2026 |
| Global settlement reached | None | Lawsuit Information Center, August 2026 |
The Defendants and the Chemicals: Who Is Being Sued and Why
The hair relaxer lawsuit 2026 targets some of the largest consumer product companies in the world. Key defendants include L’Oréal USA, Revlon, Strength of Nature, LLC, Namaste Laboratories, L.L.C., Advanced Beauty, Inc., Avlon Industries, Sally Beauty Supply LLC, and Wella Operations US LLC. Plaintiffs allege these companies knew — or should have known — that their formulations contained endocrine-disrupting and carcinogenic chemicals yet failed to warn consumers of the risks. Lawsuits also allege manufacturers aggressively marketed brands and products like Soft & Beautiful and Dark and Lovely to Black women and girls for decades.
The chemical allegations at the core of the litigation are multi-layered. Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. Though formaldehyde is in many household products, its presence is more concerning in chemical hair relaxers because it requires heat to straighten hair properly. The added heat not only releases formaldehyde gases but can also cause burns and lesions on the scalp. At the January 2026 Science Day hearing, plaintiffs’ expert Dr. Thomas Zoeller explained that when hormone disruptors are mixed with cancer-causing chemicals like formaldehyde, it is a “perfect storm” for creating a permissive environment that allows cancer cells to form and grow.
Phthalates are another class of toxic chemicals present in hair relaxers. They are a form of plasticizer used to increase the flexibility and durability of cosmetic products. Phthalates are endocrine disruptors, meaning they can interfere with the hormonal system. Parabens can also disrupt hormones and impact fertility and reproductive organs, affect birth outcomes, and increase cancer risk. Some of the most common and dangerous parabens in hair relaxers are butylparaben, methylparaben, isobutylparaben, and ethylparaben — chemicals that also disrupt the endocrine system, which can lead to endometriosis.
On the regulatory front, the FDA’s long-promised ban on formaldehyde in hair relaxers remains stalled. As of January 8, 2026, the U.S. Food and Drug Administration had again missed a deadline to propose a ban on chemicals in hair-straightening products that may pose a serious cancer risk. Its target date for the proposed rule on formaldehyde was December 31, 2025. No action has yet been taken, though an FDA spokesperson said the rule is still in the works. Meanwhile, California has banned formaldehyde in cosmetics as of January 2025 under its Toxic-Free Cosmetics Act. The European Union has reduced the amount of formaldehyde allowed in cosmetics from 0.05% to 0.001%, with all labeling and ingredient changes required to occur by July 31, 2026. Despite years of advocacy from public health groups and medical professionals, the U.S. has banned only 11 cosmetic ingredients, compared to more than 1,300 banned by the European Union.
Judge Rowland’s Unprecedented Bellwether Move: What It Signals
The most consequential procedural development of 2026 has been Judge Rowland’s decision to seize direct control of the bellwether selection process. Dissatisfied with the party-driven approach, she scrapped the alternating-picks system and selected the bellwether pool herself, with case-specific Daubert and summary judgment motions now due November 16, 2026.
A March 2025 case management order had laid out a detailed selection timeline: the court would choose the first three cases in late February 2026, with the parties taking alternating picks through mid-March, resulting in ten bellwether trial candidates. Only cases alleging uterine cancer, endometrial cancer, or ovarian cancer — filed and served by February 1, 2024 — qualified for the bellwether pool. Each side had identified 20 proposed cases by April 30, 2025, narrowed to 32 Initial Bellwether Discovery Cases by May 9, 2025.
With fact discovery on the 32-case bellwether pool having closed March 18, 2026, Judge Mary Rowland selected the initial 3 bellwether cases from the parties’ April submissions. A “Science Day” in January 2026 gave expert witnesses the opportunity to present evidence on hormone disruption and cancer links to Judge Rowland and visiting state court judges. Rowland’s move, paired with the expanded 40-case discovery pool, signals a court determined to generate verdicts representative enough to force settlement valuations.
The significance of the judge’s intervention cannot be overstated. As of July 1, 2026, there were 11,877 pending lawsuits in the hair relaxer MDL. On July 2, Judge Rowland held a status conference where expedited discovery requests, briefing deadlines, and the scope of third-party discovery were discussed. The latest notable development is that Judge Mary Rowland has lifted a discovery stay for a group of defendants after concluding that settlement discussions had not produced enough progress to justify keeping those cases frozen. A court-appointed special master continues coordinating settlement discussions across the MDL and parallel state proceedings in Illinois, Philadelphia, Georgia, and New York.
CMO 17, issued in April 2025, appointed Special Master Ellen K. Reisman for settlement coordination. Reisman previously served in similar capacities in the J&J talc, 3M Combat Arms, and DePuy hip-implant MDLs. Settlement machinery is already in place, and plaintiff-side commentators put the realistic settlement window at late 2026 into 2027 — after the Daubert rulings and, likely, the first verdicts.
The Daubert Battle: Can Plaintiffs’ Science Survive Federal Scrutiny?
The most critical legal threshold remaining in 2026 is the Daubert ruling on general causation experts. A major focus in 2026 is the court’s review of scientific evidence. Defendants are challenging expert testimony through Rule 702/Daubert motions, which are designed to evaluate whether plaintiffs’ scientific evidence is reliable and admissible. These challenges are central to the litigation because causation will play a significant role in how the cases proceed.
General causation Daubert motions were due April 1, 2026. Plaintiffs’ expert disclosures landed June 30, 2026. Defense expert disclosures are due August 3, 2026. Plaintiffs’ rebuttal expert disclosures follow in early Q4. Daubert oral argument is scheduled for late Q4 2026, with the court’s general-causation ruling expected in Q1 2027.
Both sides have filed Daubert motions challenging each other’s causation experts, with deadlines running through late 2026 and summary judgment replies due January 6, 2027. The stakes of this battle are extraordinary. If plaintiffs’ causation experts survive Daubert challenge, trials proceed. If the court excludes or substantially limits those experts under the amended Rule 702 standard, defendants gain significant leverage for summary judgment, following the pattern established in In re Acetaminophen-ASD-ADHD Products Liability Litigation.
The NIH Sister Study anchors general causation, and IARC classifies formaldehyde — long present in many relaxer formulations — as a Group 1 carcinogen. But defendants will attack causation case-by-case at the November 16 Daubert stage, and the FDA’s proposed formaldehyde ban, announced October 2023, still has not been finalized. Expect the expert rulings, not the case count, to move settlement talks.
Documentation rigor is also proving decisive at the individual case level. Usage history is the central evidentiary problem. CMO 9 Plaintiff Fact Sheet compliance requires internal consistency between PFS entries and Short Form Complaint product selections, and the court has dismissed cases for non-compliance, including one dismissal with prejudice in September 2025. The documentation burden differs from that of pharmaceutical MDLs: exposure relies on consumer behavior rather than prescription records, and lay witness development carries more weight than pharmacy databases.
New Medical Monitoring Class Action and the Road to Trial
Running parallel to the individual injury claims is a proposed consumer class action that has survived early legal challenges. A proposed consumer class action seeking economic damages, including refunds for product purchases and medical monitoring, continues to proceed alongside the injury cases. Last year, Judge Rowland largely denied a motion to dismiss that class action, allowing claims that manufacturers misled consumers about product safety to move forward. That class action is also pending in the MDL, though it has not seen new rulings recently.
A significant new trend is also reshaping the MDL’s plaintiff profile. Occupational chemical exposure claims are emerging as a dominant trend in the national hair relaxer cancer litigation, with new lawsuits increasingly filed by salon workers and cosmetologists. These cases involve women who spent years applying chemical straighteners in enclosed salon environments, often without gloves or adequate ventilation. Legal experts say these are among the most compelling claims in the MDL due to the frequency and intensity of exposure. Plaintiffs allege that daily handling of products containing endocrine-disrupting chemicals contributed to their diagnoses of uterine, ovarian, or breast cancer, and that manufacturers failed to warn professionals of the risks.
State court litigation is also running on a parallel track. As of May 1, 2026, the JPML statistical report shows 11,526 pending federal actions, with related proceedings also active in Illinois state courts, Pennsylvania, Georgia, and New York. In 2025, the Philadelphia Court of Common Pleas also consolidated hair relaxer lawsuits into a state-level mass tort. There are also hair relaxer lawsuits pending in state courts, including coordinated proceedings in Illinois and cases in Pennsylvania. State court schedules and rulings may develop separately from the federal MDL and could create additional trial pressure.
The road to trial remains on track for mid-2027. First bellwether trials are projected for mid-2027, with the standard MDL pattern of two to four trials in the first wave before settlement discussions structure around the verdict band. In the meantime, the litigation will continue to focus on expert evidence, discovery, product identification, medical record review, claimant fact sheets, and trial pool development.
Frequently Asked Questions: Hair Relaxer Lawsuit 2026
Who qualifies to file a hair relaxer lawsuit in 2026?
Based on the most current case management guidance, a qualifying claim generally requires: use of chemical hair relaxer or hair straightener products for a minimum of five continuous years prior to diagnosis; a qualifying cancer diagnosis — uterine cancer, endometrial cancer, or ovarian cancer — on or after 2005; and younger plaintiffs with longer projected life impact generally receive higher compensation. Eligibility also generally requires that the health condition was diagnosed after a period of using hair relaxer products, and that the claim falls within the statute of limitations — generally 2 to 3 years from diagnosis, but this varies by state. Uterine fibroid and hysterectomy claims are primarily being pursued in separate state-court proceedings.
What is the current status of MDL 3060 as of August 2026?
Current status: There were 11,877 plaintiffs in the federal hair relaxer MDL as of July 2026, in addition to cases pending in state courts. There is no global settlement, payout program, or established average compensation amount. What comes next: expert challenges, discovery involving additional defendants, bellwether preparation, and trial dates expected to begin creating more serious settlement pressure. As of August 2026, Judge Rowland has selected the initial 3 bellwether cases. Bellwether-specific fact discovery closed June 10, 2026, and Daubert/summary judgment motions are due November 16, 2026.
What chemicals in hair relaxers are alleged to cause cancer?
Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. Many chemicals found in relaxers act as endocrine disruptors, meaning they interfere with the body’s hormonal system. Endocrine-disrupting chemicals have been linked to reproductive harm, cancer, immune dysfunction, and developmental complications. IARC classifies formaldehyde — long present in many relaxer formulations — as a Group 1 carcinogen. The FDA has still not finalized its proposed ban on formaldehyde in hair straighteners, despite missing multiple deadlines.
Why did Judge Rowland personally select the bellwether cases instead of the parties?
Judge Rowland took direct control of choosing the “bellwether” cases — test cases tried early so both sides can gauge how juries may respond. Instead of letting the parties trade picks, the judge widened the pool of cases in discovery and pushed for more trial-ready candidates. Rowland’s move, paired with the expanded 40-case discovery pool, signals a court determined to generate verdicts representative enough to force settlement valuations. Judge Rowland’s denial of preemption and bankruptcy-coordination rulings have also preserved the merits architecture of the litigation, keeping defendants fully exposed to trial risk.
How much could a hair relaxer lawsuit settlement be worth in 2026?
No settlements have been paid out, so all figures remain projections. Attorneys estimate that many strong uterine cancer claims could fall between $150,000 and $750,000 in a negotiated mass tort settlement, with many claims likely resolving toward the lower portion of that range. Trials are expected in 2027, with potential settlement estimates ranging from $100,000 to $1.75 million. Cases involving a young plaintiff, advanced cancer, extensive treatment, infertility, recurrence, extraordinary economic loss, or death could be worth more. The most significant settlement payouts would go to the most severe cases, typically women diagnosed with uterine cancer or advanced-stage ovarian cancer. The outcome of the Daubert motions will substantially shape the bellwether trials and the eventual settlement framework. The hair-relaxer MDL is in the highest-leverage phase — bellwether discovery and Daubert briefing — which means the next 12 to 18 months will define settlement values.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.